Top-Rated StocksTop-RatedNASDAQ:ACRS Aclaris Therapeutics (ACRS) Stock Price, News & Analysis $4.00 -0.34 (-7.83%) Closing price 04:00 PM EasternExtended Trading$4.08 +0.08 (+2.05%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Aclaris Therapeutics Stock (NASDAQ:ACRS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Aclaris Therapeutics alerts:Sign Up Key Stats Today's Range$4.00▼$4.3350-Day Range$3.28▼$6.1752-Week Range$2.25▼$6.60Volume1.96 million shsAverage Volume2.58 million shsMarket Capitalization$634.44 millionP/E RatioN/ADividend YieldN/APrice Target$11.33Consensus RatingBuy Company Overview Aclaris Therapeutics is a biopharmaceutical company focused on discovering and developing treatments for immuno-inflammatory diseases. Its research programs include small-molecule therapies designed to target pathways involved in inflammation and immune responses. The company’s development portfolio has included candidates for dermatologic and other inflammatory conditions. Aclaris previously developed ESKATA, a topical treatment for raised seborrheic keratoses that received U.S. regulatory approval in 2017. Founded in 2012, Aclaris is headquartered in Wayne, Pennsylvania. Its current business is centered on pharmaceutical research and development rather than a broad portfolio of marketed medicines.AI Generated. May Contain Errors. Read More Aclaris Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks74th Percentile Overall ScoreACRS MarketRank™: 3.716843068075 of 5 starsAclaris Therapeutics scored higher than 74% of companies evaluated by MarketBeat, and ranked 155th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingBuy Consensus RatingAclaris Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.11, and is based on 3 strong buy ratings, 5 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialAclaris Therapeutics has a consensus price target of $11.33, representing about 183.3% upside from its current price of $4.00.Amount of Analyst CoverageAclaris Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Aclaris Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Aclaris Therapeutics are expected to grow in the coming year, from ($0.56) to ($0.55) per share.Price to Book Value per Share RatioAclaris Therapeutics has a P/B Ratio of 3.81. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted8.69% of the float of Aclaris Therapeutics has been sold short.Short Interest Ratio / Days to CoverAclaris Therapeutics has a short interest ratio ("days to cover") of 4.02.Change versus previous monthShort interest in Aclaris Therapeutics has recently decreased by 22.99%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAclaris Therapeutics does not currently pay a dividend.Dividend GrowthAclaris Therapeutics does not have a long track record of dividend growth. News and Social Media3.7 / 5News Sentiment0.94 News SentimentAclaris Therapeutics has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Aclaris Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 6 people have searched for ACRS on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows6 people have added Aclaris Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Aclaris Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders4.80% of the stock of Aclaris Therapeutics is held by insiders.Percentage Held by Institutions98.34% of the stock of Aclaris Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Aclaris Therapeutics' insider trading history. Receive ACRS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aclaris Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ACRS Stock News HeadlinesAclaris Therapeutics to Participate in the Jefferies Global Healthcare ConferenceNovember 12 at 7:30 AM | globenewswire.comAclaris Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 5, 2026 | marketscreener.comMDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.November 12 at 1:00 AM | Weiss Ratings (Ad)Aclaris Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate and Clinical UpdateNovember 5, 2026 | finance.yahoo.comAclaris Therapeutics (ACRS) Stock Forecast & Price TargetNovember 4, 2026 | tipranks.comAclaris Therapeutics, Inc. (ACRS) Discusses ATI-052 Proof-of-Concept Results in Atopic Dermatitis and Asthma - SlideshowOctober 29, 2026 | seekingalpha.comAclaris Reports Positive Phase 1b Results For ATI-052 In Atopic Dermatitis And Asthma; Stock DownOctober 28, 2026 | rttnews.comWedbush Cuts Price Target on Aclaris Therapeutics to $8 From $10, Keeps Outperform RatingOctober 28, 2026 | marketscreener.comMSee More Headlines ACRS Stock Analysis - Frequently Asked Questions How have ACRS shares performed this year? Aclaris Therapeutics' stock was trading at $3.01 at the beginning of the year. Since then, ACRS stock has increased by 32.9% and is now trading at $4.00. How were Aclaris Therapeutics' earnings last quarter? Aclaris Therapeutics, Inc. (NASDAQ:ACRS) released its quarterly earnings data on Thursday, November, 5th. The biotechnology company reported ($0.12) earnings per share for the quarter, beating analysts' consensus estimates of ($0.16) by $0.04. The biotechnology company earned $1.48 million during the quarter, compared to the consensus estimate of $1.27 million. Aclaris Therapeutics had a negative net margin of 1,244.09% and a negative trailing twelve-month return on equity of 59.19%. When did Aclaris Therapeutics IPO? Aclaris Therapeutics (ACRS) raised $75 million in an initial public offering (IPO) on Wednesday, October 7th 2015. The company issued 5,000,000 shares at $14.00-$16.00 per share. Who are Aclaris Therapeutics' major shareholders? Top institutional shareholders of Aclaris Therapeutics include BML Capital Management LLC (7.84%), State Street Corp (2.33%), HighTower Advisors LLC (0.16%) and Alps Advisors Inc. (0.14%). Insiders that own company stock include Braden Michael Leonard and Anand Mehra. View institutional ownership trends. How do I buy shares of Aclaris Therapeutics? Shares of ACRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Aclaris Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aclaris Therapeutics investors own include NVIDIA (NVDA), Micron Technology (MU), Pfizer (PFE), Palantir Technologies (PLTR), Tesla (TSLA), Advanced Micro Devices (AMD) and Intel (INTC). Company Calendar Last Earnings11/05/2026Today11/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1d) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 ACRS's financial health is in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ACRS CIK1557746 Webwww.aclaristx.com Phone(484) 324-7933Fax484-320-2344Employees73Year Founded2012Price Target and Rating Average Price Target for Aclaris Therapeutics$11.33 High Price Target$16.00 Low Price Target$8.00 Potential Upside/Downside+183.3%Consensus RatingBuy Rating Score (0-4)3.11 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($0.58) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$64.92 million Net Margins-1,244.09% Pretax Margin-1,244.09% Return on Equity-59.19% Return on Assets-42.19% Debt Debt-to-Equity RatioN/A Current Ratio5.09 Quick Ratio5.09 Sales & Book Value Annual Sales$7.83 million Price / Sales81.03 Cash FlowN/A Price / Cash FlowN/A Book Value$1.05 per share Price / Book3.81Miscellaneous Outstanding Shares158,610,000Free Float150,999,000Market Cap$634.44 million OptionableOptionable Beta0.96 Social Links 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (NASDAQ:ACRS) was last updated on 11/12/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredMany investors are about to lose everythingTwenty five years ago, this analyst predicted the fiber optic boom and called Amazon before it became a househ...Porter & Company | SponsoredWatch This NowJensen Huang, the man who launched the AI boom, just called what Elon Musk is chasing "the final frontier of A...StocksToTrade | SponsoredManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...Monument Traders Alliance | SponsoredProfessor Who Lectured at Harvard Warns: Sell These 10 Stocks Before Dec. 10Joel Litman, a professor who has lectured at Harvard and Wharton, is warning of a $33 trillion grid crisis tha...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aclaris Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aclaris Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
